Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market Intelligence

Set Alert for Market Intelligence

Amgen Sees Acceleration In US Biosimilars Market

The US marketplace for biosimilars is accelerating faster than the EU at a similar point in its existence, based on approval rates, Amgen has observed in a preview of its 2022 trends in biosimilars report that also offers new data on pricing and uptake.

Market Intelligence Biosimilars

Competition Intensifies As Access Increases For US Biosimilars

At an eventful time for US biosimilars, a fresh wave of players entering the market is expected to both increase competition and broaden access, AmerisourceBergen’s senior vice president for global emerging therapies and channel strategy Beth McMahon tells Generics Bulletin.

Biosimilars United States

Risperidone Rises See UK Prices Treble In May

Prices for generic risperidone as much as trebled in the UK in May, leading off increases that also included exemestane and brimonidine tartrate.

Market Intelligence Pricing Strategies

Inflation Impact Must Be Considered During Generics Pricing, Says Canadian Study

Canadian provinces must consider the impact of inflation on generic drugs during the next round of off-patent price setting, says a study from Aviseo and the Canadian Generic Pharmaceutical Association.

Generic Drugs Pricing Strategies

Solifenacin Surges As UK Sees Huge Price Rises In April

Multiple different generics saw triple-digit-percentage price rises that led UK averages to as much as quadruple in April 2022, according to the latest figures from WaveData. Solifenacin and ibandronic acid led the month’s steepest increases.

Market Intelligence Pricing Strategies

UK Pramipexole Prices Plummet In March

Multiple presentations of pramipexole modified-release tablets saw their average UK trade prices nosedive in March, according to the latest figures from market researcher WaveData, which also revealed the reason for the dramatic declines.

Market Intelligence Pricing Strategies

HHS Study Finds Medicare Part D Underutilizing Biosimilars

Research from the US HHS has found that millions of dollars could be saved by Medicare by increasing the biosimilar coverage of Part D plans.

Biosimilars Medicare

Trio Of Generics See UK Prices Double In February

Three different generics saw their average UK trade price more than double in February 2022, according to the latest figures from WaveData, with losartan/hydrochlorothiazide, ascorbic acid and amoxicillin leading the month’s biggest rises.

Market Intelligence Pricing Strategies

Hikma Warns Of Renewed Pricing Pressure On US Generics

Hikma has warned of renewed pressure on generics in the US after a “gradual worsening of the pricing environment” in 2021. However, the company still managed to achieve growth of a tenth in its generics segment last year, on the back of key launches.

Market Intelligence United States
See All
UsernamePublicRestriction

Register